| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.02 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.03 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.03 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.071 | 0.03 |